| abstract |
The present invention relates to an agent for the treatment and/or prevention of pollakiuria comprising a compound having an antagonism to an EP 1 receptor which is a prostaglandin E 2 receptor subtype. A compound having an antagonism to an EP 1 receptor antagonistically acts on an EP 1 receptor which is a prostaglandin PGE 2 receptor subtype and significantly shows a suppressive activity for urination frequency in models where pollakiuria is induced. Therefore, it is effective for the treatment and/or prevention of pollakiuria (that which is due to nurogenic bladder, nervous bladder, stimulated bladder, unstable bladder, benign prostatic hypertrophy, etc.). |